Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …

Consensus guidelines recommend dopamine agonists (DAs) as the mainstay treatment for
prolactinomas. In most patients, DAs achieve tumor shrinkage and normoprolactinemia at …

Simple Summary This review updates recent advances in the pathogenesis, diagnosis, and
therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine …

Survival for patients with aggressive pituitary tumours (APT) and pituitary carcinomas (PC)
has significantly improved following the increasing use of temozolomide (TMZ) since the first …

Pituitary tumors (PT) are mostly benign, although occasionally they demonstrate aggressive
behavior, invasion of surrounding tissues, rapid growth, resistance to conventional …

Especially given the rarity of aggressive pituitary tumors and carcinomas, and the scarcity of
available data, the ESE guidelines are of tremendous help, providing clinicians with vital …

Pituitary tumors (PT) represent in, the majority of cases, benign tumors for which surgical
treatment still remains, except for prolactin-secreting PT, the first-line therapeutic option …

A subset of pituitary neuroendocrine tumors (PitNETs) have an aggressive behavior,
showing resistance to treatment and/or multiple recurrences in spite of the optimal use of …

A small subset of lactotroph adenomas is resistant to dopamine agonists (DA) and can also
demonstrate aggressive or even malignant behavior. The implicated mechanisms are not …